CompletedPhase 1NCT01566877

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers

Studying Marburg hemorrhagic fever

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Sarepta Therapeutics, Inc.
Principal Investigator: Mohamed Al-Ibrahim, MD
SNBL
Intervention: AVI-7288(drug)
Enrollment: 40 enrolled
Eligibility: 18-50 years · All sexes
Timeline: 2013 – 2014

Study locations (1)

SNBL Clinical Pharmacology Center, Inc., Baltimore, Maryland, United States

Collaborators

United States Department of Defense

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01566877 on ClinicalTrials.gov

Other trials for Marburg hemorrhagic fever

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE2NCT06620003
A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults
Albert B. Sabin Vaccine Institute

See all trials for Marburg hemorrhagic fever →

← Back to all trials